Antisense Oligonucleotides

Biogen Pledges $2 Billion Manufacturing Investment in North Carolina

3 days ago talkbio0Tagged Antisense Oligonucleotides, Aortic Valve Insufficiency, Automation, Biogen, Biotechnology, expansion, gene therapy, Investments, Manufacturing, North Carolina, Research Triangle Park

Biogen; manufacturing investment; North Carolina; Research Triangle Park; biotechnology; antisense oligonucleotides; gene therapy; automation; AI; expansion

Ultragenyx’s GTX-102 Shows Promising Results in Mid-Stage Angelman Syndrome Study, Pivotal Study on the Horizon

1 year ago talkbio0Tagged Angelman Syndrome, Antisense Oligonucleotides, Behavioral Improvement, Cognitive Improvement, Gross Motor Improvement, GTX-102, mid-stage study, Sleep Improvement, Ultragenyx

Ultragenyx, GTX-102, Angelman Syndrome, Mid-Stage Study, Pivotal Study, Antisense Oligonucleotide, Cognitive Improvement, Behavioral Improvement, Sleep Improvement, Gross Motor Improvement

Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors

1 year ago talkbio0Tagged Antisense Oligonucleotides, Genetic Epilepsy Drug, Infantile Severe Myoclonic Epilepsy, investor, Level of interest, Positive Clinical Trial, Seizures, STK-001, Stoke

Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm